Last reviewed · How we verify
Abiraterone acetate suspension Formulation 1
Androgen receptor inhibitor
Androgen receptor inhibitor Used for Prostate cancer.
At a glance
| Generic name | Abiraterone acetate suspension Formulation 1 |
|---|---|
| Sponsor | Cougar Biotechnology, Inc. |
| Drug class | CYP17 inhibitor |
| Target | CYP17 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
Abiraterone acetate is a potent inhibitor of the enzyme CYP17, which is involved in the biosynthesis of androgens. By inhibiting CYP17, abiraterone acetate reduces the production of androgens, such as testosterone and dihydrotestosterone, which are involved in the growth and spread of prostate cancer cells.
Approved indications
- Prostate cancer
Common side effects
- Fatigue
- Hypertension
- Diarrhea
- Nausea
- Muscle spasm
Key clinical trials
- TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer (PHASE3)
- A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies (PHASE1)
- A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: